Fig. 1

Mean and 95% CI of vaccine efficacy estimates with and without imputations for baseline seronegative (sero−) and baseline seropositive (sero+) subjects. Estimates were obtained from 1000 realisations of the final BRT model trained on 50% of non-cases and 75% of cases and using 10-fold cross-validation, tc = 16, lr = 0.0005, bf = 0.75. a Sensitivity (sens), specificity (spec) and proportion of correct classifications (pcc) among cases, non-cases and overall. b Vaccine efficacy estimates for baseline seropositive and baseline seronegative subjects separately. c Vaccine efficacy estimates for baseline seropositive and baseline seronegative subjects by age using 2–8, 9–11, 12–16 and 9–16 years age groups. d Vaccine efficacy estimates by serotype for baseline seropositive and baseline seronegative subjects of all ages (2–16 years). e Vaccine efficacy estimates by serotype for baseline seropositive and baseline seronegative subjects 2–8 years old. f Vaccine efficacy estimates by serotype for baseline seropositive and baseline seronegative subjects 9–16 years old